Company
Headquarters: Lhasa, China
Employees: 733
CN¥11.51 Billion
CNY as of Jan. 1, 2025
US$1.58 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Tibet Rhodiola Pharmaceutical Holding Co. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. It offers biological products, Tibetan medicine, Chinese medicine, and chemical medicine products. The company was founded in 1999 and is based in Lhasa, China.
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥2.94 B |
| EBITDA | CN¥1.24 B |
| Gross Profit TTM | CN¥2.78 B |
| Profit Margin | 25.07% |
| Operating Margin | 50.38% |
| Quarterly Revenue Growth | 2.40% |
Tibet Rhodiola Pharmaceutical Holding Co. has the following listings and related stock indices.
Stock: SSE: 600211 wb_incandescent